12JJ5048). References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002. CA Cancer J Clin 2005, 55:74–108.CrossRef 2. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143–154.CrossRef 3. Bagnato VS, Kurachi C, Ferreira J, Sankarankutty AK, Zucoloto S, De Castro e Silva O: New photonic technologies for the treatment and diagnosis of hepatic diseases: an overview of the experimental work performed in collaboration, between Physics Institute of Sao Carlos and Ribeirao Preto Faculty of Medicine of the University of Sao Paulo. Acta Cir Bras 2006,21(Suppl 1):3–11. 4. Allison RR, Sibata CH: Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagn Photodyn Ther 2010, 7:61–75.CrossRef 5. Chen B, Roskams T, de Witte Selleck PF477736 PA: Antivascular
tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol 2002, 76:509–513.CrossRef 6. Konan YN, Gurny R, Allemann E: State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B check details Biol 2002, 66:89–106.CrossRef 7. Soncin M, Polo L, Reddi E, Jori G, Kenney ME, Cheng G, Rodgers MA: Effect of the delivery system on the biodistribution of Ge(IV) octabutoxy-phthalocyanines in tumour-bearing mice. Cancer Lett 1995, 89:101–106.CrossRef 8. Hatakeyama H, Akita H, Harashima H: A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011, 63:152–160.CrossRef 9. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P: Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta see more 1805, 2010:53–71. 10. Kennedy JC, Pottier RH, Pross DC: Photodynamic therapy with endogenous protoporphyrin
IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990, 6:143–148.CrossRef 11. Ascencio M, Collinet P, Farine MO, Mordon S: Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med 2008, 40:332–341.CrossRef 12. De Rosa FS, Bentley MV: Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res 2000, 17:1447–1455.CrossRef 13. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M: Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008, 26:612–621.CrossRef 14. Couleaud P, Morosini V, Frochot C, Richeter S, Raehm L, Durand JO: Silica-based nanoparticles for photodynamic therapy applications. Nanoscale 2010, 2:1083–1095.CrossRef 15. Deng X, Xiong L, Lin L, Xiong G, Miao X: Photosan-II loaded hollow silica nanoparticles: preparation and its effect in killing for QBC939 cells.
No related posts.